A Novel Inactivated Intranasal Respiratory Syncytial Virus Vaccine Promotes Viral Clearance without Th2 Associated Vaccine-Enhanced Disease
Figure 2
Intranasal vaccination of mice with NE-RSV results in RSV-specific antibody responses.
Mice were immunized with NE-RSV containing 105 virus particles at Day 0 and Day 28. In (A), the levels of RSV specific antibodies (IgG+IgM) in serum were determined at weeks 2, 4, 6, 8, and 10 via ELISA using purified RSV protein. In (B), serum samples were serially diluted to obtain endpoints titers. In (C), RSV-specific IgA, IgG2a, IgG1, and IgE were assessed at week 8 via isotype-specific ELISA. In (D), IgG2a and IgG1 antibodies specific for RSV F and G were assessed at week 8 via isotype-specific ELISA using purified RSV F and G glycoproteins. In (E), RSV-specific IgA responses in bronchoalveolar lavage samples (BAL) were assessed using an isotype-specific ELISA. Each time point represents the mean of a minimum of 5 samples +/− SEM, and the experiment was repeated with similar results. * = P<0.01.